An 8 week study to evaluate the effectiveness of adding montelukast to inhaled corticosteroid (ICS) or to ICS/long-acting beta 2-agonist therapy in adult subjects with asthma and allergic rhinitis.

Trial Profile

An 8 week study to evaluate the effectiveness of adding montelukast to inhaled corticosteroid (ICS) or to ICS/long-acting beta 2-agonist therapy in adult subjects with asthma and allergic rhinitis.

Completed
Phase of Trial: Phase IV

Latest Information Update: 10 Dec 2013

At a glance

  • Drugs Montelukast (Primary)
  • Indications Allergic rhinitis; Asthma
  • Focus Therapeutic Use
  • Acronyms Nutrilock
  • Sponsors Merck & Co
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 21 Aug 2009 Actual patient number changed from 440 to 313 as reported by ClinicalTrials.gov.
    • 30 Oct 2008 Actual patient number (440) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top